eXoZymes Inc(EXOZ)

POST11.970.48+4.18%16:00 EST

11.49-0.98-7.86%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Exozymes CEO Joins Beryl Elites Panel on AI in Life Sciences
  Reuters · 12-15
  Exozymes CEO Joins Beryl Elites Panel on AI in Life Sciences
- Exozymes Achieves 99% Conversion in Scaled Cell-Free Biomanufacturing
  Reuters · 12-12
  Exozymes Achieves 99% Conversion in Scaled Cell-Free Biomanufacturing
- Slack Capital Calls eXoZymes a Once-in-a-Lifetime Biotech Opportunity
  Reuters · 11-19
  Slack Capital Calls eXoZymes a Once-in-a-Lifetime Biotech Opportunity
- Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology
  Reuters · 11-19
  Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology
- eXoZymes Inc trading resumes
  TIPRANKS · 11-19
  eXoZymes Inc trading resumes
- Exozymes Inc. posts Q3 net loss of $2.29 million
  Reuters · 11-14
  Exozymes Inc. posts Q3 net loss of $2.29 million
- Exozymes Inc. Names Tyler Korman as CSO and Amy Lunzer as Chief of Staff
  Reuters · 11-14
  Exozymes Inc. Names Tyler Korman as CSO and Amy Lunzer as Chief of Staff
- eXoZymes Inc. - Common Stock Q3 EPS $(0.27)
  Benzinga · 11-14
  eXoZymes Inc. - Common Stock Q3 EPS $(0.27)
- Exozymes Inc. Highlights AI-Driven Enzyme Innovation in Executive Interview
  Reuters · 11-12
  Exozymes Inc. Highlights AI-Driven Enzyme Innovation in Executive Interview
- Exozymes Inc. to Report Third Quarter 2025 Results
  Reuters · 11-11
  Exozymes Inc. to Report Third Quarter 2025 Results
- Exozymes Inc. CEO Joins AI in Life Sciences Panel at Beryl Elites Investment Conference
  Reuters · 10-31
  Exozymes Inc. CEO Joins AI in Life Sciences Panel at Beryl Elites Investment Conference
- eXoZymes Inc trading halted, volatility trading pause
  TIPRANKS · 10-24
  eXoZymes Inc trading halted, volatility trading pause
- ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview
  Reuters · 10-03
  ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview
- Exozymes Inc. Appoints Senior Leaders to BioMADE Governance Committees, Strengthening Role in Cell-Free Biomanufacturing
  Reuters · 10-01
  Exozymes Inc. Appoints Senior Leaders to BioMADE Governance Committees, Strengthening Role in Cell-Free Biomanufacturing
- eXoZymes Inc. - Common Stock Q2 EPS $(0.28) Down From $(0.22) YoY
  Benzinga · 08-13
  eXoZymes Inc. - Common Stock Q2 EPS $(0.28) Down From $(0.22) YoY
- Exozymes Inc. Reports Q2 2025 Net Loss of $2.36M, Operating Expenses Rise by $1.20M
  Reuters · 08-13
  Exozymes Inc. Reports Q2 2025 Net Loss of $2.36M, Operating Expenses Rise by $1.20M
- eXoZymes Inc. to Host Second Quarter 2025 Update Webinar Led by CEO Michael Heltzen
  Reuters · 08-08
  eXoZymes Inc. to Host Second Quarter 2025 Update Webinar Led by CEO Michael Heltzen
- eXoZymes Inc. Achieves Breakthrough in Biomanufacturing: Produces 4 Grams of NCT with Over 99% Purity Using AI-Driven Platform
  Reuters · 07-29
  eXoZymes Inc. Achieves Breakthrough in Biomanufacturing: Produces 4 Grams of NCT with Over 99% Purity Using AI-Driven Platform
- Exozymes Inc. Conducted Annual Stockholders Meeting
  Reuters · 07-28
  Exozymes Inc. Conducted Annual Stockholders Meeting
- eXoZymes Inc. Achieves Breakthrough in Biomanufacturing with Rapid Production of NCT Using AI-Engineered Enzymes
  Reuters · 07-23
  eXoZymes Inc. Achieves Breakthrough in Biomanufacturing with Rapid Production of NCT Using AI-Engineered Enzymes
Company Profile
Company Name
eXoZymes Inc
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.invizyne.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
- -
- 12-17
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 12-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 11-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 11-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 10-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 07-28
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-08
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-26
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-20
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 04-25
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 04-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 04-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-31
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

1D
5D
Day
Week
Month

Loading ...

High

12.40

Open

12.40

Volume%

0.67

Low

11.24

12.47

T/O Rate

0.08%

To The Moon

eXoZymes Inc(EXOZ)

Company Profile

Most Discussed